MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.repc.2025.11.011

Медицинская библиотека · Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology · 2026

Management of lipid profile and lipid-lowering therapy in the diabetic population of a primary care center according to cardiovascular risk category (SCORE2-Diabetes vs. SCORE).

Cunha André, Pedro Correia João, Calheiros Lobo Joana, Botelho Elias Francisca, Costa Leite Pedro, Brazão Catarina, Lucas Ana, B Loyens Dinis

СтатьяСравнительное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION AND

OBJECTIVES

Cardiovascular diseases are among the leading causes of morbidity and mortality and represent a significant economic burden; having type 2 diabetes is a major risk factor. After identifying that a considerable proportion of patients with type 2 diabetes were not achieving their recommended LDL-C targets, a study was designed to assess LDL-C levels in relation to target values defined by cardiovascular risk (CVR) category and the lipid-lowering therapy (LLT) prescribed.

METHODS

This cross-sectional study included a random sample of 245 patients with diabetes, aged 40-69 years, who had recent lipid profile and renal function tests and were being followed at a primary care (PC) center. Exclusion criteria were established for macrovascular disease, significant renal impairment, or microvascular complications in multiple territories.

RESULTS

It was observed that 59.2% of patients had LDL-C levels above target, of whom over 75% were classified as high or very high risk. Among these, 27.6% were not receiving any LLT, and only 9% were being treated with high-intensity statins, either alone or in combination with ezetimibe. Among patients receiving this combination, 78.9% achieved target LDL-C levels. CVR category was higher in the SCORE model than the SCORE2-Diabetes in 56.7% of cases, significantly influencing the proportion of patients with LDL-C at target (20.0% vs. 40.8%, respectively; p=0.014).

CONCLUSIONS

Lipid-lowering therapy remains underutilized in patients with type 2 diabetes, particularly those at high and very high CVR, as over half fail to achieve LDL-C targets. Notably, the SCORE model appears to overestimate CVR compared with SCORE2-Diabetes.

Для цитирования: Cunha André, Pedro Correia João, Calheiros Lobo Joana, Botelho Elias Francisca, Costa Leite Pedro, Brazão Catarina, Lucas Ana, B Loyens Dinis. Management of lipid profile and lipid-lowering therapy in the diabetic population of a primary care center according to cardiovascular risk category (SCORE2-Diabetes vs. SCORE).. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology. 2026. DOI: 10.1016/j.repc.2025.11.011.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.